Scarica l'app Stockscreener
14.80
0.47%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ETNB Giù?
Forum
Previsione
Precedente Chiudi:
$14.87
Aprire:
$14.85
Volume 24 ore:
11.89M
Relative Volume:
2.96
Capitalizzazione di mercato:
$2.19B
Reddito:
-
Utile/perdita netta:
$-174.61M
Rapporto P/E:
-7.5127
EPS:
-1.97
Flusso di cassa netto:
$-165.54M
1 W Prestazione:
-0.34%
1M Prestazione:
+73.71%
6M Prestazione:
+196.30%
1 anno Prestazione:
+98.92%
Intervallo 1D:
$14.75
$14.87
Intervallo di 1 settimana:
$14.75
$14.89
Portata 52W:
$4.16
$15.06
89 Bio Inc Stock (ETNB) Company Profile
Nome
89 Bio Inc
Settore
Industria
Telefono
(415) 432-9270
Indirizzo
655 MONTGOMERY STREET, SAN FRANCISCO, CA
Confronta ETNB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
14.80 | 2.21B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-14 | Iniziato | Goldman | Neutral |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Ripresa | BofA Securities | Buy |
| 2024-01-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-06-13 | Iniziato | Evercore ISI | Outperform |
| 2022-05-12 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-26 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-04-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-19 | Iniziato | Raymond James | Strong Buy |
| 2020-09-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-23 | Iniziato | BTIG Research | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2019-12-09 | Iniziato | BofA/Merrill | Neutral |
| 2019-12-09 | Iniziato | Oppenheimer | Outperform |
| 2019-12-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-12-09 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
89 Bio Inc Borsa (ETNB) Ultime notizie
Investors Purchase High Volume of Put Options on 89BIO (NASDAQ:ETNB) - Defense World
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash - Ariva
89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal - MSN
Kala Bio Stock Just Plunged 89% Today – Here’s What Happened - Stocktwits
Why 89bio Inc. stock is rated strong buy2025 Biggest Moves & Verified Entry Point Detection - newser.com
Technical analysis overview for 89bio Inc. stock2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Will 89bio Inc. stock split attract more investorsWeekly Trend Recap & Daily Profit Maximizing Trade Tips - newser.com
Is 89bio Inc. stock attractive for retirement portfoliosWeekly Stock Report & Momentum Based Trading Ideas - newser.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PINC, MTSR, ETNB on Behalf of Shareholders - GlobeNewswire Inc.
Backtesting results for 89bio Inc. trading strategiesQuarterly Trade Review & Short-Term High Return Strategies - newser.com
How 89bio Inc. stock reacts to global recession fearsBear Alert & Community Consensus Picks - newser.com
Measuring 89bio Inc.’s beta against major indicesEarnings Overview Report & Daily Profit Maximizing Trade Tips - newser.com
89bio, Inc. Hits New 52-Week High of $15.06, Up 76.62% - Markets Mojo
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB) - PR Newswire
How to integrate 89bio Inc. into portfolio analysis toolsJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Applying chart zones and confluence areas to 89bio Inc.Forecast Cut & Free Technical Pattern Based Buy Signals - newser.com
Real time breakdown of 89bio Inc. stock performance2025 Historical Comparison & Entry Point Strategy Guides - newser.com
Roche To Buy 89bio For Up To $3.5 Billion - Pulse 2.0
89Bio (ETNB) Soars 86 Percent to Historic High on $3.5-Billion Roche Merger - MSN
Will 89bio Inc. continue its uptrendPortfolio Update Summary & Verified High Yield Trade Plans - newser.com
Published on: 2025-09-19 14:02:20 - newser.com
Has 89bio Inc. found a price floor2025 Market Trends & Technical Confirmation Trade Alerts - newser.com
89bio Stock Price, Quotes and Forecasts | NASDAQ:ETNB - Benzinga
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc.ETNB - Business Wire
Dow Update: Is 89bio Inc trading at a discountWeekly Trade Analysis & Reliable Price Breakout Alerts - خودرو بانک
Roche to Buy 89bio for Up to $3.5 Billion in Obesity Push - MSN
89bio Inc. stock chart pattern explainedMarket Growth Summary & AI Forecast for Swing Trade Picks - newser.com
Roche Makes Major MASH Bid, Offering $2.4bn For 89bio - insights.citeline.com
Roche’s 89bio Buyout: Building A Combo-Ready Metabolic Franchise Beyond GLP-1 Wars (RHHBY) - Seeking Alpha
Roche Scoops Up 89bio In A $2.4 Billion Deal - Finimize
89bio: Pegozafermin MASH Drug Advancement Nets Roche Acquisition (NASDAQ:ETNB) - Seeking Alpha
Roche To Buy 89bio in $3.5 Billion Deal - USA Herald
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push - Benzinga
Roche Expands Cardiometabolic Pipeline With 89bio Acquisition (OTCMKTS:RHHBY) - Seeking Alpha
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline - Yahoo Finance
MASH dash speeds up as Roche acquires 89bio for up to $3.5B - BioWorld MedTech
Roche deal to buy 89bio boosts MASH space (ETNB:NASDAQ) - Seeking Alpha
Is ETNB Stock a Bargain or a Risk? - StocksToTrade
Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion - The Wall Street Journal
89bio Stock Surge: Time to Invest? - timothysykes.com
Roche to acquire liver drug developer 89bio for up to $3.5 billion - Reuters
Why Did 89bio Stock Nearly Double In Value Today? - Stocktwits
ETNB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 89bio, Inc. Is Fair to Shareholders - Business Wire
Roche to Buy Biopharmceutical Firm 89bio in $3.5 Billion Deal - Bloomberg.com
Roche enters into a definitive merger agreement to acquire - GlobeNewswire
Roche Holding AG agreed to acquire 89bio, Inc. for $2.2 billion in a tender offer transaction. - MarketScreener
Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders - Business Wire
Roche to buy biopharmaceutical firm 89bio in $3.5bn deal - Moneyweb
89 Bio Inc Azioni (ETNB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):